"G(M2) Ganglioside" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycosphingolipid that accumulates due to a deficiency of hexosaminidase A or B (BETA-N-ACETYLHEXOSAMINIDASES), or GM2 activator protein, resulting in GANGLIOSIDOSES, heredity metabolic disorders that include TAY-SACHS DISEASE and SANDHOFF DISEASE.
| Descriptor ID |
D005678
|
| MeSH Number(s) |
D09.400.410.420.025.475.400 D10.390.470.025.475.400 D10.570.877.360.025.475.400
|
| Concept/Terms |
G(M2) Ganglioside- G(M2) Ganglioside
- Ganglioside GM2
- GM2, Ganglioside
- Tay-Sachs Disease Ganglioside
- Ganglioside, Tay-Sachs Disease
- Tay Sachs Disease Ganglioside
|
Below are MeSH descriptors whose meaning is more general than "G(M2) Ganglioside".
Below are MeSH descriptors whose meaning is more specific than "G(M2) Ganglioside".
This graph shows the total number of publications written about "G(M2) Ganglioside" by people in this website by year, and whether "G(M2) Ganglioside" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 2001 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "G(M2) Ganglioside" by people in Profiles.
-
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.
-
Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus. mBio. 2015 Mar 03; 6(2):e02356.
-
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 01; 19(9):2370-80.
-
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
-
Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
-
Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer. Gene Ther. 1996 Sep; 3(9):769-74.